Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics

ObjectivesPosterior reversible encephalopathy syndrome (PRES) is a rare but potentially severe complication of VEGF-pathway inhibition. A recent FAERS analysis supported PRES as a probable class effect of angiogenesis inhibitors but found no association with continuous VEGFR affinity, did not formal...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ji Li, Yan Cheng, Yunzhou Yang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-07-01
Edice:	Frontiers in Pharmacology
Témata:	disproportionality analysis FAERS fruquintinib pharmacovigilance posterior reversible encephalopathy syndrome ramucirumab
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1887454/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!